Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Other

Inventiva Updates Lanifibranor NASH Development Program; Galectin Completes Ph2b/3 NAVIGATE Study Enrollment; Novo Signs Stemcell Deal with Fujifilm

Here is a brief preview of this blast: Three cardiometabolic-related news items have been observed: Inventiva announced changes to the clinical development of lanifibranor, including a new Ph3 trial in NASH and compensated cirrhosis (view press release); Galectin announced enrollment completion for its Ph2b/3 NAVIGATE study evaluating belapectin in patients with liver cirrhosis caused by NASH (view press release; CT.gov record); and Fujifilm Cellular Dynamics announced an iPSC-derived cell therapy license agreement with Novo Nordisk (view press release). Below, FENIX provides highlights and insights for the respective news items, including readthrough from Inventiva’s new NASH clinical development strategy.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.